The volume available in icosahedral virus capsids limits the size of viral genomes. To overcome this limitation, viruses have evolved strategies to increase their coding capacity by using more than one ORF while keeping the genome length constant. The assembly of virus capsids requires the coordinated interaction of a large number of subunits to generate a highly ordered structure in which the viral genome can be enclosed. To understand this process, it is essential to know which viral and nonviral components are involved in the assembly reaction. Here, we show that the adeno-associated virus (AAV) encodes a protein required for capsid formation by means of a nested, alternative ORF of the cap gene. Translation is initiated at a nonconventional translation start site, resulting in the expression of a protein with a calculated molecular weight of 23 kDa. This protein, designated assembly-activating protein (AAP), is localized in the host cell nucleolus, where AAV capsid morphogenesis occurs. AAP targets newly synthesized capsid proteins to this organelle and in addition fulfils a function in the assembly reaction itself. Sequence analysis suggests that also all other species of the genus Dependovirus encode a homologous protein in their cap gene. The arrangement of different ORFs that encode capsid proteins and an assembly factor within the same mRNA facilitates a timely coordinated expression of the components involved in the assembly process.
The volume available in icosahedral virus capsids limits the size of viral genomes. To overcome this limitation, viruses have evolved strategies to increase their coding capacity by using more than one ORF while keeping the genome length constant. The assembly of virus capsids requires the coordinated interaction of a large number of subunits to generate a highly ordered structure in which the viral genome can be enclosed. To understand this process, it is essential to know which viral and nonviral components are involved in the assembly reaction. Here, we show that the adeno-associated virus (AAV) encodes a protein required for capsid formation by means of a nested, alternative ORF of the cap gene. Translation is initiated at a nonconventional translation start site, resulting in the expression of a protein with a calculated molecular weight of 23 kDa. This protein, designated assembly-activating protein (AAP), is localized in the host cell nucleolus, where AAV capsid morphogenesis occurs. AAP targets newly synthesized capsid proteins to this organelle and in addition fulfils a function in the assembly reaction itself. Sequence analysis suggests that also all other species of the genus Dependovirus encode a homologous protein in their cap gene. The arrangement of different ORFs that encode capsid proteins and an assembly factor within the same mRNA facilitates a timely coordinated expression of the components involved in the assembly process.
assembly-activating protein | adeno-associated virus | capsid assembly | alternative open reading frame | translation initiation A deno-associated virus (AAV) is a small, nonenveloped parvovirus harboring a single-stranded DNA genome of ≈4.7 kb. It has gained particular attention because recombinant AAV vectors represent one of the most promising viral vector systems for somatic gene therapy. The AAV capsid is composed of 60 capsid protein subunits, designated VP1, VP2, and VP3, that are arranged in a T = 1 icosahedral symmetry. Alternative splicing and translation initiation of VP2 at a nonconventional ACG initiation codon promote the expression of VP1, VP2, and VP3 in the appropriate stoichiometric ratio of 1:1:10 (1-3). The commonly accepted concept of AAV virion assembly suggests that empty capsids are formed into which singlestranded DNA genomes are then introduced (4) . Neither of these processes is well understood at the molecular level, however. Upon AAV infection, capsids are first detected in nucleoli and then spread into the nuclear compartment with time (5) . This assembly process does not require the expression of viral genes other than the cap gene (5, 6 ). Yet controversial observations as to whether different VP proteins are required for the assembly reaction have been published. Initially, it was reported that VP3 alone is not able to assemble capsids (6, 7), whereas, more recently, two groups reported capsid formation of VP3 in the absence of VP1 and VP2 (8, 9) . In the latter cases, expression of VP3 alone was achieved by preventing VP1 and VP2 expression through genetic alteration of the VP1 and VP2 encoding sequence of the cap gene. So far, however, no rational explanation has been found for these conflicting results. The present study resolves the contradiction by identifying an AAV gene product that is encoded by an alternative ORF of the cap gene, initiated upstream of the VP3 coding sequence. The gene product is essential for AAV capsid assembly and virus reproduction.
Results
Expression of VP3 Is Not Sufficient for AAV2 Capsid Assembly. In an attempt to clarify the question of whether VP3 is sufficient for capsid formation, we reinvestigated AAV2 capsid assembly using the VP3 expression constructs described by Warrington et al. (9) (Fig. 1A,  pVP3 ) and Ruffing et al. (6) (Fig. 1A, pKEX-VP3 ). For comparison, the complete wild-type AAV2 genome (Fig. 1A, pTAV2 .0) was used. By transfecting 293T cells with pVP3-containing the entire cap gene with mutated VP1 and VP2 translation start codonscapsids were formed showing titers similar to those of wild-type AAV2 (Fig. 1C) although only VP3 could be detected (Fig. 1B) . This confirmed the report of Warrington et al. (9) . In contrast, expression of VP3 by pKEX-VP3, which harbors only the part of the cap gene starting with the VP3 translation start codon, did not yield detectable amounts of capsids (Fig. 1C) , which is in agreement with our previous reports (6, 7) . Therefore, these data suggest that a factor included in the AAV sequence upstream of the VP3 translation initiation codon is responsible for promoting AAV2 capsid formation after transfection of pVP3.
To verify this hypothesis, we gradually deleted upstream AAV2 genome sequences and analyzed capsid assembly (Fig. 1 , pCMV-VP3 constructs). In line with the aforementioned results, expression of VP3 alone by transfecting pCMV-VP3/2809, which is equivalent to pKEX-VP3, did not induce detectable capsid formation, whereas a construct with a 5′ extension of only 44 nucleotides did ( Fig. 1C ; pCMV-VP3/2765). The formation of capsids from pCMV-VP3/2809, which might not react with the monoclonal antibody (mAb) A20-based ELISA, was excluded by sucrose density gradient fractionation and Western blot analysis of assembly products. mAb B1 reacting with a C-terminal epitope of the VP proteins (10) again did not detect VP1 or VP2 expression in the deletion constructs ( Fig. 1B ; see wild type and pCMV-VP for comparison). These data indicate that, in addition to VP3, a short sequence element upstream of the VP3 translation start site is required for capsid assembly.
Complementation of VP3 Capsid Assembly in Trans. To further characterize this element, we attempted to provide the assemblypromoting activity in trans. To this end, an expression clone comprising the N terminus of VP2 (including the implied Nterminal extension of VP3) and a portion of VP3 (EcoNI-BsiWI fragment; see Fig. 2A ) was fused to gfp ( Fig. 2A, pVP2N-gfp) . The assembly-deficient plasmid pCMV-VP3/2809 was then complemented with decreasing amounts of pVP2N-gfp in 293T cells. By coexpressing VP2N-gfp and VP3, capsid assembly of the assembly-negative mutant pCMV-VP3/2809 could be rescued ( Fig. 2A, Right) . Assembly was even detected at a 500-fold reduced amount of cotransfected pVP2N-gfp plasmid. The recon- stituted VP3 capsids showed the same morphology as capsids assembled with all three capsid proteins as analyzed by negative staining and electron microscopy (Fig. S1 ).
A Protein Encoded by ORF2 of the AAV cap Gene Promotes VP3 Capsid Formation. The trans-complementation assay made it possible to modify the EcoNI-BsiWI fragment of the cap gene without affecting the VP3 sequence and thereby to determine the nature of the putative assembly factor. In addition to the VP2 N-terminal part (encoded by ORF1 of the cap gene), a protein translated from an alternative ORF or a nontranslated RNA transcribed from the cap gene was also considered. To distinguish between these possibilities, we first eliminated expression of proteins from ORFs other than ORF1 or formation of a nontranslated RNA by changing the codon usage for ORF1 such that the expression of VP proteins was preserved ( Fig. 2B ; pVP2N/ORF1cm). Although VP2N-gfp expression increased (Fig. 2B , Center) and VP3 levels were normal, capsid assembly was not detected with this helper construct (Fig. 2B, Right) . Even when pVP2N/ORF1cm was cotransfected with pCMV-VP3/2809 in lower molar ratios, no capsids were formed. Additionally, introducing stop codons into ORF1 of the cap gene, which prevents VP2N-gfp expression, did not prevent capsid assembly (Fig. S2A ). These results demonstrate that expression of the N-terminal part of VP2 is not involved in VP3-based capsid formation. In a second set of experiments, we tested complementation of VP3 assembly by a construct in which the codons were modified to suppress protein(s) encoded from ORFs other than ORF2 and consequentially also to change the resulting RNA sequence ( Fig. 2B ; pVP2N/ORF2cm). Coexpression of this assembly helper construct with VP3 fully restored capsid assembly (Fig. 2B, Right) . Moreover, stop mutants in ORF2 prevented the formation of capsids (Fig. S2B ). These observations support the conclusion that a protein encoded by ORF2 of the cap gene provides the capsid assembly helper function.
Sequence analysis revealed that the predicted ORF2 has no canonical translation start site and that the EcoNI-BsiWI fragment did not contain the C-terminal part of the ORF. Therefore, we amplified the complete, predicted ORF2 from AAV2 nucleotide position 2717-3340 of the AAV2 genome by PCR and fused it to an AU1-tag. A noncanonical translation initiation codon CTG embedded in a translation initiation context (11) at position 2729-2731 was assumed as a possible translation start and was additionally mutated to ATG and to TTG to modulate the putative protein expression (Fig. 2C) . The different expression levels were demonstrated using mAb against the AU1-tag for the constructs with a CTG or an ATG initiation codon ( Fig. 2C ; Center, anti-AU1). Expression from construct pORF2/TTG-AU1 was below the detection level. Cotransfection of the ORF2-containing plasmids with the VP3 expression plasmid yielded VP3 capsid formation in correlation with the amounts of expressed protein: Slightly lower titers were observed after cotransfection with the CTG-containing plasmid and ≈10
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-fold reduced capsid formation after cotransfection with the plasmid harboring a TTG start codon. This finding corroborates the conclusion that a protein product of ORF2 promotes the capsid assembly process. The protein was designated assembly-activating protein (AAP). A polyclonal antiserum raised against a peptide of ORF2 finally confirmed the protein nature of AAP by reaction with the ATG-initiated, AU1-tagged, full-length AAP and also the truncated AAP expressed from pVP2N-gfp [ Fig. 2C , Center; anti-AAP (AAP anti-serum)]. Expression of AAP using constructs with the CTG initiation codon was close to detection level and with the TTG initiation codon was below detection level.
AAP Is Required for Capsid Assembly Within the Full-Length AAV
Genome. To determine the role of the newly identified AAV gene product in the context of the entire AAV genome, we incorporated the ORF1 codon-modified sequence (the EcoNI-BsiWI fragment) into the AAV genome (pTAV2.0), thereby obtaining plasmid pTAV/ORF1cm (Fig. 3A ): This construct should express the known AAV2 VP and Rep proteins, but should be deficient in the synthesis of AAP. Indeed, the four Rep proteins were correctly expressed; however, the expression pattern of the three VP proteins was slightly altered. Using the polyclonal anti-AAP serum, we could directly prove that endogenous AAP was expressed from the wild-type plasmid, but not from the codon-modified plasmid (Fig.  3B ). After transfection of pTAV/ORF1cm in combination with the empty vector (pBS), no capsid formation was detected, but in combination with pVP2N-gfp (providing truncated AAP), capsid assembly was restored (Fig. 3C) . Complementation with mutant plasmids that were unable to express the AAP protein (due to codon modification or introduction of a stop codon) did not in- Western blot analysis of VP protein expression was performed using mAb B1, which detects all three capsid proteins. In extracts of pKEX-VP3-, pCMV-VP3/2765-, and pCMV-VP3/2809-transfected cells, mAb B1 reacted with two polypeptide bands migrating slower than VP3. These polypeptides were a consequence of higher VP3 levels, which were not completely denatured and cannot result from VP1 or VP2 expression because the respective coding sequences were deleted. (C) Capsid formation was quantified by ELISA based on mAb A20. Detection limit: 5 × 10 7 capsids/mL Means ± SDs of at least three independent experiments are shown; asterisks indicate constructs for which no capsids could be detected.
duce capsid formation whereas AAP-expressing plasmids rescued capsid formation (Fig. 3D) . This result was confirmed by an AAV genomic plasmid with a stop mutation in ORF2 of the cap gene that prevented the expression of AAP but not the expression of the VP proteins (Fig. S3) , showing that capsid formation in the complete viral genome context depended on the expression of AAP.
AAP Targets VP Proteins to the Nucleolus and Is Required for the Capsid Assembly Reaction. Following AAV infection, capsid assembly was first detected in the nucleoli of infected cells (5) . Capsid protein VP3 expressed alone was distributed throughout the cell nuclei and the cytoplasm but was excluded from nucleoli ( Fig. 4B ; pCMV-VP3/2809). No capsids were detected in those cells with the capsid-specific mAb A20. When AAP was coexpressed (by transfection of pVP2N-gfp), part of the VP3 protein was translocated to nucleoli and capsids were formed. Interestingly, the AAP protein was also located in the nucleoli (Fig.  4C) , suggesting that AAP cotransports VP proteins to the nucleoli. It has previously been reported that fusion of a nuclear localization signal (NLS) to the N terminus of VP3 promotes nuclear translocation of VP3 and capsid assembly (12) . We repeated this experiment and observed strong nuclear accumulation of NLS-VP3, which, however, was excluded from nucleoli ( Fig. 4B ; pCMV-NLS-VP3). In contrast to Hoque and colleagues (12), we did not observe any capsid formation. Coexpression of AAP, however, targeted a portion of the VP3 proteins to the nucleoli, where capsid formation was also detected (Fig. 4B) . To test whether the transfer of VP proteins to nucleoli is sufficient for capsid formation, a nucleolar localization signal derived from HIV Rev protein was fused to the VP3 N terminus ( Fig. 4B ; pCMV-NoLS-VP3). This modified VP3 protein accumulated at least partially in the nucleoli of HeLa cells, but this was not sufficient for capsid assembly (Fig. 4B) . Coexpression of AAP again promoted capsid formation, clearly indicating that the AAP protein not only targets VP proteins to the nucleoli but also plays an additional, positive role in the assembly reaction. These results were confirmed in a quantitative manner (Fig. S4) .
Discussion
On the basis of the AAV2 genome sequence (13) and genetic studies (14, 15) , it was believed for more than 25 years that AAV2 expresses only four nonstructural proteins and the three 1,0E+14 structural proteins VP1, VP2, and VP3. The present study has identified an additional AAV gene product encoded by ORF2 of the cap gene, which is required for AAV2 capsid assembly (Fig.  5 ). This small protein stimulates the transport of unassembled VP proteins into the nucleolus for capsid assembly. The nucleolus may provide factors used in the assembly process, such as chaperones involved in different kinds of assembly reactions occurring in this organelle (16) . Promising candidates include nucleophosmin and nucleolin, which were found to be associated with capsids (17, 18) . AAP-independent targeting of VP3 to the nucleus or nucleolus by tagging VP3 with appropriate peptide signals was not sufficient for capsid formation. This suggests that AAP not only stimulates transport of VP proteins to the nucleolus, but also plays a role in the assembly process itself. However, the mechanism by which AAP promotes capsid assembly remains elusive. On the basis of the morphogenesis of other viruses (19, 20) , AAP could constitute a scaffold for VP proteins in the assembly process. Alternatively, it may chaperone or nucleate the assembly reaction by providing correct VP protein folding or by forming an assembly core. Coincidentally, nucleation could form the basis for generating a portal complex through which the genome is inserted into the capsid. Such a structure is still missing in AAV, although it has to be postulated if encapsidation occurs in preformed capsids. Overall, the role of this assembly factor in the complete AAV virion assembly process represents a topic for future investigations.
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An intriguing aspect is the use of a nonconventional translation initiation codon (CTG) for AAP expression. Within the Fig. 3 . Trans-complementation of the full-length AAV2 genome containing an ORF1 codon-modified cap gene fragment. (A) Schematic of plasmid pTAV2.0, harboring the wild-type AAV2 genome, and of plasmid pTAV/ ORF1cm, containing the ORF1 codon-modified EcoNI-BsiWI fragment of the cap gene (shaded box). Plasmids were cotransfected with the indicated constructs into 293T cells. (B) Western blot analysis of VP protein expression was performed using mAb B1. AAP and AAPtru were detected with polyclonal anti-AAP serum. (C and D) Capsid formation was quantified by ELISA based on mAb A20. Means ± SDs of at least three independent experiments are shown; asterisks indicate samples for which no capsids could be detected. Localization of total expressed capsid proteins using polyclonal VP antiserum (VPs, green) and of assembled capsids using mAb A20 (capsid, red). (C) Detection of AAP-AU1 using a mAb against the AU1-tag (anti-AU1, red) and of nucleoli using polyclonal fibrillarin antibody (anti-fibrillarin, green).
cap gene it is preceded by the weak initiation codon ACG for VP2 and succeeded by the ATG initiation codon for VP3 (Fig.  5) . A translation strategy involving a leaky scanning or shunting mechanism (21) would ensure the expression of all three proteins from one transcript. Through the arrangement of different ORFs within the same mRNA, a functional unit is generated, facilitating a timely coordinated expression of the viral components involved in the assembly process. Moreover, this composition exploits the limited coding capacity of the small AAV genome in a highly economical manner and gives an example of the hidden coding potential of mRNA. A database search suggests that all members of the genus Dependovirus encode a homologous protein in their cap gene (Fig. S5 ) whereas members of other genera within the parvovirus family do not. The amino acid sequence of AAP is well conserved among AAV serotypes 1-13. The most conserved elements include a highly hydrophobic domain, a high content of conserved serines, threonines, and prolines and a rather basic character of the C-terminal portion of the molecule. It remains to be shown whether this sequence conservation reflects constraints imposed by the VP protein structure (encoded by ORF1) or by possible functions of AAP. Revealing a capsid assembly factor has a strong impact on the understanding of AAV morphogenesis and genome organization. Beyond that, the finding indicates restrictions for developing capsid-modified AAV gene transfer vectors by peptide insertions or capsid protein shuffling, which impair AAP function and thus prevent production of the respective recombinant viral particles.
Materials and Methods
Plasmids and Cloning. Plasmids pTAV2.0 (22), pVP3 (9), pCMV-VP (5), pKEX-VP3 (6), and pBS (Stratagene) have been described previously. For deletion analysis, the HindIII-BsiWI fragment from pVP3 (with mutated VP1 and VP2 translation start codons) was subcloned into the HindIII-BsiWI backbone of pCMV-VP, resulting in construct pCMV-VP/1882. Constructs pCMV-VP3/2193 and pCMV-VP3/2596 were generated by subcloning the DraI-BsiWI or the EcoNI (blunt)-BsiWI fragment from pVP3 into the HindIII (blunted)-BsiWI backbone of pCMV-VP. For further deletions, pVP3 was used as a template for site-directed mutagenesis reactions. Mutagenesis was performed using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's manual. For each mutation, two complementary PCR primers were designed to generate a new HindIII restriction site at the designated area. HindIII-BsiWI fragments from mutated plasmids were then subcloned into the HindIII-BsiWI backbone of pCMV-VP, resulting in constructs pCMV-VP3/2611, pCMV-VP3/2696, pCMV-VP3/2765, and pCMV-VP3/2809.
For generation of construct pVP2N-gfp, EcoNI and BsiWI restriction sites were introduced into the multiple cloning site of vector pEGFP-N1 (BD Biosciences). Afterward, the EcoNI-BsiWI fragment from pTAV2.0 was inserted.
Constructs pVP2N/ORF1cm and pVP2N/ORF2cm are based on pVP2N-gfp, with the difference that codon-modified AAV2 EcoNI-BsiWI fragments synthesized by Geneart were inserted into the corresponding vector backbone (see sequences in Fig. S6) .
Plasmids pVP2N/ORF1stopA-D and pVP2N/ORF2stopA-C were created by site-directed mutagenesis of template pVP2N-gfp using two complementary PCR primers that included the desired substitutions. In each case, the EcoNI-BsiWI fragment was then cloned into the EcoNI-BsiWI backbone of pVP2N-gfp.
For generation of the constructs pORF2/CTG-AU1, pORF2/ATG-AU1, and pORF2/TTG-AU1, PCRs were performed with template pTAV2.0 and forward primer 5′-GGATCGCAAGCTTATTTTGGTCAGACTGGAGACGCAGACTCAGTACC-TGACCC-3′, 5′-GGATCGCAAGCTTATTTTGGTCAGAATGGAGACGCAGACTCAG-3′, or 5′-GGATCGCAAGCTTATTTTGGTCAGATTGGAGACGCAGACTCAG-3′ and reverse primer 5′-GCGGTGTCTCGAGTTATATATAGCGATAGGTGTCGGGTGAG-GTATCCATACTGTGGCACCATGAAGAC-3′. The HindIII-XhoI-digested amplification products were inserted into the HindIII-XhoI backbone of pBS-CMVs, which was generated by inserting a 560-bp BamHI human cytomegalovirus promoter fragment from pHCMV-Luci (kindly provided by K. Butz, German Cancer Research Centre, Heidelberg, Germany) into the BamHI site of pBluescript II SK+ (Stratagene).
Constructs pTAV/ORF1cm and pTAV/ORF2stopB were created by cloning the EcoNI-BsiWI fragments derived from pVP2N/ORF1cm and pVP2N/ORF2-stopB, respectively, into the EcoNI-BsiWI backbone of pTAV2.0.
Cloning of construct pCMV-NLS-VP3 was carried out by site-directed mutagenesis reaction with template pCMV-VP3/2809 and complementary PCR primers 5′-GGAATTCGATATCAAGCTTGCCATGGCACCACCAAAGAAGAAGCG-AAAGGTTATGGCTACAGGCAGTGG-3′ and 5′-CCACTGCCTGTAGCCATAACCTT-TCGCTTCTTCTTTGGTGGTGCCATGGCAAGCTTGATATCGAATTCC-3′. Then the HindIII-BsiWI fragment was subcloned from the amplicon into the HindIII-BsiWI backbone of pCMV-VP3/2809. The cap gene product NLS-VP3 contains the amino acid sequence MAPPKKKRKV at the N terminus of VP3.
The approach for generating pCMV-NoLS-VP3 was the same as that for pCMV-NLS-VP3; however, primer pair 5′-GGAATTCGATATCAAGCTTGCCAT-GGCACGGCAGGCCCGGCGGAATAGACGGAGACGGTGGCGGGAACGGCAGCG-GATGGCTACAGGCAGTGG-3′ and 5′-CCACTGCCTGTAGCCATCCGCTGCCGTTC-CCGCCACCGTCTCCGTCTATTCCGCCGGGCCTGCCGTGCCATGGCAAGCTTGATA-TCGAATTCC-3′ was used. Accordingly, the cap gene product NoLS-VP3 contains the amino acid sequence MARQARRNRRRRWRERQR at the N terminus of VP3.
Cell Culture. HeLa and 293T cells were maintained at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated FCS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine.
Quantification of AAV2 Capsids. Capsid titers were determined using the AAV2 titration ELISA kit (Progen) as described previously (23) .
Transfection and Preparation of Virus Supernatants. Cells (5 × 10 5 /dish) were seeded in 6-cm dishes 24 h before transfection. The 293T cells were transfected by calcium phosphate precipitation (24) . For HeLa cells, transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's manual. In the case of promoter p40-dependent transcription of the cap gene (pTAV2.0, derivates thereof and pVP3), cells were infected with adenovirus type 5 (Ad5) (multiplicity of infection = 10). After additional incubation for 48 h, cells were harvested in the medium and lysed by three freeze-thaw cycles (−80°C and 37°C). Lysates were incubated at 56°C for 30 min to inactivate Ad5. Cell debris was removed by centrifugation at 10,000 × g for 5 min.
Preparation of Polyclonal Antibody. The polyclonal anti-AAP was generated by immunization of a guinea pig with a peptide comprising the sequence GKDSSTTTGDSDPRDSTS conjugated to Keyhole limpet hemocyanin following standard procedures.
Analysis of Protein Expression. Identical portions of harvested cells were processed for SDS-PAGE. Protein expression was analyzed by Western blot assay using the monoclonal antibodies A69, B1, or anti-AU1 (Covance) or polyclonal antibody anti-AAP as described previously (25) .
Immunofluorescence Analysis. HeLa cells were cultivated for 24 h on coverslips before transfection. After 20 h, cells were fixed with 100% methanol (10 min, −20°C) and washed with PBS (18.4 mM Na 2 HPO 4 , 10.9 mM KH 2 PO 4 , 125 mM NaCl). Incubation with primary antibodies was performed for 1 h at room temperature or overnight at 4°C. Coverslips were washed three times with PBS and thereafter incubated with appropriate secondary antibodies (purchased from Dianova or Molecular Probes) for 1 h at room temperature. Coverslips were washed again, dipped into 100% ethanol, and embedded in Permafluor mounting medium (Beckman Coulter). Confocal images (0.3-μm sections) were obtained with a Leica TCS SP2 laser scanning microscope and further processed using Adobe Photoshop CS software.
Sucrose Density Gradient Analysis. Assembled and nonassembled capsid proteins were separated in linear sucrose gradients. Collected fractions were analyzed using native (mAb A20) or denaturing (mAb B1) Western dot blot assay, respectively (26) .
Preparation and EM Analysis of Empty AAV2 Capsids. AAV2 empty capsids were purified using two consecutive double-sucrose cushions and negatively stained (2% uranyl acetate) for EM analysis according to ref. 7.
